A novel precision oncology platform has been developed to forecast chemotherapy responses in esophageal adenocarcinoma (EAC) patients, addressing the high rate of chemoresistance in this lethal cancer type. By integrating patient-derived organoids with tumor microenvironment components, including stromal fibroblasts and extracellular matrix, the organ chip model simulates the complex in vivo cancer milieu. This advancement offers a promising tool for personalized treatment planning, aiming to improve survival rates and quality of life. The collaborative study features contributions from experts including Donald Ingber and Lorenzo Ferri.